Bronchiectasis is a disease associated with chronic progressive and irreversible dilatation of
the bronchi and is characterised by chronic infection and associated inflammation. The …

Bronchiectasis is a heterogeneous chronic disease. Heterogeneity characterises
bronchiectasis not only in the stable state but also during exacerbations, despite evidence …

Background Community-acquired pneumonia (CAP) is a frequent cause of death worldwide,
and in sub-Saharan Africa particularly. Human immunodeficiency virus infection (HIV) and …

Background Infection is the most common cause of mortality within the first year after lung
transplantation (LTx). The management of perioperative antibiotic therapy is a major issue …

Background Aboriginal Australians are reported to have a high burden of chronic airway
diseases. However, prescribing patterns and related outcomes of airway directed inhaled …

Aim. The present study aimed to investigate the relation between FACED and BSI scores,
which were developed to measure the severity of bronchiectasis, and systemic inflammation …

Background: Noncystic fibrosis bronchiectasis (NCFB) is still considered an “orphan
disease” in pediatric age. Objective: The study describes the clinical and functional features …

Introduction: Non-cystic fibrosis bronchiectasis (NCFB) results from a permanent and
progressive destruction of the airways leading to poor lung function. NCFB is characterized …

Aims Non‐cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive respiratory
disorder characterised by irreversibly and abnormally dilated airways, persistent cough …

N-acetyl-L-cysteine (NAC) was initially introduced as a treatment for mucus reduction and
widely used for chronic respiratory conditions associated with mucus overproduction …